SAN DIEGO & SINGAPORE–(BUSINESS WIRE)–ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics, today announced that Dan MacLeod, Ph.D., the company�s vice president of discovery, will present at the 7th Annual CAR-TCR Summit taking place September 19-22, 2022 in Boston.
The CAR TCR Summit is a multi-day, industry leading comprehensive forum that explores discovery through to commercialization to deliver safe, effective, and commercially viable CAR and TCR therapies.
At the summit, Dr. MacLeod will participate in several sessions:
ImmunoScapes differentiated Deep Immunomics platform utilizes the companys proprietary combinatorial barcoding technology to enable the discovery and in-depth characterization of rare cancer-specific T-cells at high resolution. ImmunoScapes platform is able to simultaneously evaluate tens of millions of T-cells in blood samples from hundreds of cancer patients to identify clinically relevant T-cell clones. The corresponding T-cell receptors (TCRs) are currently being evaluated and prioritized to form a diverse pipeline of TCR-T-cell therapies covering multiple antigens and HLA restrictions.
To see the full summit schedule, and to register for the event, please visit https://car-tcr-summit.com/.
To set up a time to meet with Dr. MacLeod or ImmunoScape CEO Choon-Peng Ng at the summit, please email info@immunoscape.com.
To learn more about ImmunoScape, please visit https://immunoscape.com/.
About ImmunoScape
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company’s proprietary Deep Immunomics technology and machine learning platforms enable highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. For more information, please visit https://immunoscape.com/.
Contacts
Kalyn Kolek for ImmunoScape
kos@anzupartners.com
CHITTAGONG, BANGLADESH - Media OutReach Newswire - 2 May 2024 - Helle Thorning-Schmidt, Denmark's first…
Unleashing the Potential of the Cloud with Simplified Access, Enhanced Performance and Streamlined Management SINGAPORE…
SL25 recognises and celebrates the 25 best projects of steward leadership excellence by for-profit organisations.…
HONG KONG SAR - Media OutReach Newswire - 2 May 2024 - On 30 April…
KUALA LUMPUR, Malaysia--(BUSINESS WIRE)--#airtransport--Milrem Robotics, Europe’s leading robotics and autonomous systems developer, is to introduce…
DUBLIN--(BUSINESS WIRE)--The "Singapore Loyalty Programs Market Intelligence and Future Growth Dynamics Databook - 50+ KPIs…